Gustafson; Kirk R.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Gustafson; Kirk R..The latest application filed is for "hypoxia-inducible factor 1 (hif-1) inhibitors".

Company Profile

1.25.17

Gustafson; Kirk R. - Frederick MD
Gustafson; Kirk R - Frederick MD
Gustafson; Kirk R. - Mt. Airy MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Hypoxia-inducible factor 1 (HIF-1) inhibitors Grant 10,246,463 - Gustafson , et al.	2019-04-02
Hypoxia-inducible Factor 1 (hif-1) Inhibitors App 20180093995 - Gustafson; Kirk R. ; et al.	2018-04-05
Biologically active macrolides, compositions, and uses thereof Grant 9,820,965 - Boyd , et al. November 21, 2	2017-11-21
Method of inhibiting ABCG2 and other treatment methods Grant 9,314,448 - Henrich , et al. April 19, 2	2016-04-19
Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment Grant 9,238,069 - Sayers , et al. January 19, 2	2016-01-19
Biologically Active Macrolides, Compositions, And Uses Thereof App 20150374661 - Boyd; Michael R. ; et al.	2015-12-31
Biologically Active Macrolides, Compositions, And Uses Thereof App 20140243284 - Boyd; Michael R. ; et al.	2014-08-28
Biologically active macrolides, compositions, and uses thereof Grant 8,741,947 - Boyd , et al. June 3, 2	2014-06-03
Nuclear factor kappa B pathway inhibitor composition and use of same Grant 8,729,053 - Henrich , et al. May 20, 2	2014-05-20
Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof Grant 8,609,716 - Boyd , et al. December 17, 2	2013-12-17
Method Of Inhibiting Abcg2 And Other Treatment Methods App 20130274323 - Henrich; Curtis J. ; et al.	2013-10-17
Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer Grant 8,470,888 - Henrich , et al. June 25, 2	2013-06-25
Method Of Sensitizing Cancer Cells To The Cytotoxic Effects Of Death Receptor Ligands In Cancer Treatment App 20130039883 - Sayers; Thomas Joseph ; et al.	2013-02-14
Chondropsin-class Antitumor V-atpase Inhibitor Compounds, Compositions And Methods Of Use Thereof App 20130023500 - Boyd; Michael R. ; et al.	2013-01-24
Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof Grant 8,278,348 - Boyd , et al. October 2, 2	2012-10-02
Nuclear Factor Kappa B Pathway Inhibitor Composition And Use Of Same App 20110190240 - Henrich; Curtis J. ; et al.	2011-08-04
Chondropsin-class Antitumor V-atpase Inhibitor Compounds, Compositions And Methods Of Use Thereof App 20110034547 - Boyd; Michael R. ; et al.	2011-02-10
Method Of Inhibiting Abcg2 And Other Treatment Methods App 20100317732 - Henrich; Curtis J. ; et al.	2010-12-16
Biologically Active Macrolides, Compositions, And Uses Thereof App 20100298248 - Boyd; Michael R. ; et al.	2010-11-25
Biologically active macrolides, compositions, and uses thereof Grant 7,790,764 - Boyd , et al. September 7, 2	2010-09-07
CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF App 20090197940 - Boyd; Michael R. ; et al.	2009-08-06
Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof Grant 7,521,475 - Boyd , et al. April 21, 2	2009-04-21
CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF App 20070142347 - Boyd; Michael R. ; et al.	2007-06-21
Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof Grant 7,205,334 - Boyd , et al. April 17, 2	2007-04-17
Biologically active macrolides, compositions, and uses thereof Grant 7,144,918 - Boyd , et al. December 5, 2	2006-12-05
Biologically active microlides, compositions, and uses thereof App 20060205707 - Boyd; Michael R. ; et al.	2006-09-14
Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof Grant 6,987,096 - Boyd , et al. January 17, 2	2006-01-17
Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof App 20050176810 - Boyd, Michael R ; et al.	2005-08-11
Calanolide and related antiviral compounds, compositions, and uses thereof Grant 6,774,141 - Boyd , et al. August 10, 2	2004-08-10
Biologically active macrolides, compositions, and uses thereof App 20040087566 - Boyd, Michael R ; et al.	2004-05-06
Calanolide and related antiviral compounds, compositions, and uses thereof Grant 6,673,830 - Boyd , et al. January 6, 2	2004-01-06
Calanolide and related antiviral compounds, compositions, and uses thereof App 20020086898 - Boyd, Michael R. ; et al.	2002-07-04
Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins Grant 6,245,737 - Boyd , et al. June 12, 2	2001-06-12
Anti-cyanovirin antibody Grant 5,998,587 - Boyd , et al. December 7, 1	1999-12-07
Antiviral naphthoquinone compounds, compositions and uses thereof Grant 5,869,522 - Boyd , et al. February 9, 1	1999-02-09
Nucleic acids encoding antiviral proteins and peptides, vectors and host cells comprising same, and methods of producing the antiviral proteins and peptides Grant 5,821,081 - Boyd , et al. October 13, 1	1998-10-13
Antiretroviral naphthoquinone compounds compositions and uses thereof Grant 5,783,598 - Boyd , et al. July 21, 1	1998-07-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.